146 related articles for article (PubMed ID: 24197907)
1. The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.
Bonanno L; Costa C; Majem M; Sanchez JJ; Gimenez-Capitan A; Rodriguez I; Vergnenegre A; Massuti B; Favaretto A; Rugge M; Pallares C; Taron M; Rosell R
Oncotarget; 2013 Oct; 4(10):1572-81. PubMed ID: 24197907
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer.
Wei J; Costa C; Shen J; Yu L; Sanchez JJ; Qian X; Sun X; Zou Z; Gimenez-Capitan A; Yue G; Guan W; Rosell R; Liu B
Br J Cancer; 2014 May; 110(11):2662-8. PubMed ID: 24809779
[TBL] [Abstract][Full Text] [Related]
3. Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).
Kotoula V; Krikelis D; Karavasilis V; Koletsa T; Eleftheraki AG; Televantou D; Christodoulou C; Dimoudis S; Korantzis I; Pectasides D; Syrigos KN; Kosmidis PA; Fountzilas G
BMC Cancer; 2012 Aug; 12():342. PubMed ID: 22866924
[TBL] [Abstract][Full Text] [Related]
4. Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.
Bonanno L; Costa C; Majem M; Sanchez JJ; Rodriguez I; Gimenez-Capitan A; Molina-Vila MA; Vergnenegre A; Massuti B; Favaretto A; Rugge M; Pallares C; Taron M; Rosell R
BMC Cancer; 2016 May; 16():312. PubMed ID: 27179511
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
Papadaki C; Sfakianaki M; Ioannidis G; Lagoudaki E; Trypaki M; Tryfonidis K; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J
J Thorac Oncol; 2012 Apr; 7(4):663-71. PubMed ID: 22425915
[TBL] [Abstract][Full Text] [Related]
6. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.
Karachaliou N; Bracht JWP; Fernandez Bruno M; Drozdowskyj A; Gimenez Capitan A; Moran T; Carcereny E; Cobo M; Domine M; Chaib I; Ramirez JL; Camps C; Provencio M; Vergnenegre A; Lopez-Vivanco G; Majem M; Massuti B; Rosell R
J Thorac Oncol; 2019 Feb; 14(2):304-310. PubMed ID: 30472259
[TBL] [Abstract][Full Text] [Related]
7. High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer.
Schouten PC; Vollebergh MA; Opdam M; Jonkers M; Loden M; Wesseling J; Hauptmann M; Linn SC
Mol Cancer Ther; 2016 Jan; 15(1):190-8. PubMed ID: 26637364
[TBL] [Abstract][Full Text] [Related]
8. 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.
Pennington KP; Wickramanayake A; Norquist BM; Pennil CC; Garcia RL; Agnew KJ; Taniguchi T; Welcsh P; Swisher EM
Gynecol Oncol; 2013 Mar; 128(3):493-9. PubMed ID: 23246380
[TBL] [Abstract][Full Text] [Related]
9. DNA repair pathways to regulate response to chemoradiotherapy in patients with locally advanced head and neck cancer.
Cirauqui B; Margelí M; Quiroga V; Quer A; Karachaliou N; Chaib I; Ramírez JL; Muñoz A; Pollán C; Planas I; Drozdowsky A; Rosell R
Tumour Biol; 2016 Oct; 37(10):13435-13443. PubMed ID: 27465548
[TBL] [Abstract][Full Text] [Related]
10. Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Wang LR; He LJ; Wang Y; Li YY; Lou Y; Zhang GB; Li Y; Chen J
Cancer Chemother Pharmacol; 2015 Jul; 76(1):163-70. PubMed ID: 26003539
[TBL] [Abstract][Full Text] [Related]
11. DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance.
Wang S; Liu F; Zhu J; Chen P; Liu H; Liu Q; Han J
Med Sci Monit; 2016 Jun; 22():1999-2005. PubMed ID: 27289442
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
Rosell R; Molina MA; Costa C; Simonetti S; Gimenez-Capitan A; Bertran-Alamillo J; Mayo C; Moran T; Mendez P; Cardenal F; Isla D; Provencio M; Cobo M; Insa A; Garcia-Campelo R; Reguart N; Majem M; Viteri S; Carcereny E; Porta R; Massuti B; Queralt C; de Aguirre I; Sanchez JM; Sanchez-Ronco M; Mate JL; Ariza A; Benlloch S; Sanchez JJ; Bivona TG; Sawyers CL; Taron M
Clin Cancer Res; 2011 Mar; 17(5):1160-8. PubMed ID: 21233402
[TBL] [Abstract][Full Text] [Related]
14. BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
Karachaliou N; Costa C; Gimenez-Capitan A; Molina-Vila MA; Bertran-Alamillo J; Mayo C; Massuti B; Majem M; Carcereny E; Moran T; Sanchez JJ; Viteri S; Gasco A; Wannesson L; Souglakos J; Jimeno J; Rosell R;
J Thorac Oncol; 2013 Mar; 8(3):295-300. PubMed ID: 23407556
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 expression associated with the prognostic value of platinum-based chemotherapy for stage II-IV non-small cell lung cancer: A meta-analysis.
Huang Z; Xiong G
Int J Biol Markers; 2022 Jun; 37(2):170-177. PubMed ID: 35404148
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.
Carser JE; Quinn JE; Michie CO; O'Brien EJ; McCluggage WG; Maxwell P; Lamers E; Lioe TF; Williams AR; Kennedy RD; Gourley C; Harkin DP
Gynecol Oncol; 2011 Dec; 123(3):492-8. PubMed ID: 21920589
[TBL] [Abstract][Full Text] [Related]
17. The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Bonanno L; Costa C; Majem M; Favaretto A; Rugge M; Rosell R
Ann Oncol; 2013 Apr; 24(4):1130-2. PubMed ID: 23429864
[No Abstract] [Full Text] [Related]
18. Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma.
Wei B; Han Q; Xu L; Zhang X; Zhu J; Wan L; Jin Y; Qian Z; Wu J; Gao Y; Zhou J; Chen X
BMC Cancer; 2015 Apr; 15():331. PubMed ID: 25925371
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
[TBL] [Abstract][Full Text] [Related]
20. Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients.
Agulló-Ortuño MT; García-Ruiz I; Díaz-García CV; Enguita AB; Pardo-Marqués V; Prieto-García E; Ponce S; Iglesias L; Zugazagoitia J; López-Martín JA; Paz-Ares L; Nuñez JA
Cancer Chemother Pharmacol; 2020 Mar; 85(3):525-535. PubMed ID: 31832811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
